Fluorescent GLP1R/GIPR dual agonist probes reveal cell targets in the pancreas and brain.
de Bray A., Roberts AG., Armour S., Tong J., Huhn C., Gatin-Fraudet B., Roßmann K., Shilleh AH., Jiang W., Figueredo Burgos NS., Trott JPP., Viloria K., Nasteska D., Pearce A., Miyazaki S., Tomlinson JW., Owen DM., Nieves DJ., Ast J., Cyranka M., Epanchintsev A., Ämmälä C., Reimann F., Soykan T., Ladds G., Adriaenssens AE., Trapp S., Jones B., Broichhagen J., Hodson DJ.
Dual agonists targeting glucagon-like peptide-1 receptor (GLP1R) and glucose-dependent insulinotropic polypeptide receptor (GIPR) are breakthrough treatments for patients with type 2 diabetes and obesity. Compared to GLP1R agonists, dual agonists show superior efficacy for glucose lowering and weight reduction. However, delineation of dual agonist cell targets remains challenging. Here, we develop and test daLUXendin and daLUXendin+, non-lipidated and lipidated fluorescent GLP1R/GIPR dual agonist probes, and use them to visualize cellular targets. daLUXendins are potent GLP1R/GIPR dual agonists that advantageously show less functional selectivity for mouse GLP1R over mouse GIPR. daLUXendins label rodent and human pancreatic islet cells, with a signal intensity of β cells > α cells = δ cells. Systemic administration of daLUXendin strongly labels GLP1R+ and GIPR+ neurons in circumventricular organs characterized by an incomplete blood-brain barrier but does not penetrate the brain beyond labelling seen with single (ant)agonists. At the single-molecule level, daLUXendin targets endogenous GLP1R-GIPR nanodomains, which differ in organization and composition from those targeted by a single agonist. daLUXendins reveal dual agonist targets in the pancreas and brain and exclude a role for brain penetration in determining the superior efficacy of dual agonists, shedding new light on different modes of action of dual agonists versus single agonists.